Genitourinary Cancer Research - Penn State Cancer Institute
Genitourinary Cancer Research
Research into genitourinary and prostate cancer at Penn State Cancer Institute is conducted by the genitourinary cancer team. See current clinical trials and members of that team here.
Clinical Trials
The COVID-19 and Cancer Consortium (CCC19) Registry
Phase III Study of PET-Directed Local or Systemic Therapy Intensification in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)
Prospective evaluation of potential effects of repeated gadoliniumbased contrast agent (GBCA) administrations of the same GBCA on motor and cognitive functions in neurologically normal adults in comparison to a non-GBCA exposed control group ODYSSEY
Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer
Radiopaque Hydrogel Rectal Spacer for Prostate Cancer Radiation Image Guidance
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
NRG-GU011: A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)
A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE) EA8212
A Phase II/III trial of Durvalumab and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy EA8192
Phase III Randomized Trial of Stereotactic ablative radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma (SOAR)
A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)
Phase 1, open label clinical trial to treat Stage IV cancer patients with multiple patient-specific mutated cell surface proteins with chimeric antibodies
NRG-GU013: The Phase III 'High Five Trial' Five Fraction Radiation for High-Risk Prostate Cancer
Creation of a Clinical and Pathologic Tissue Microarray Registry for Radical Cystectomy Specimens
Disease Team Members
| First Name | Last Name | Title | Role | ||
|---|---|---|---|---|---|
 |
Joseph | Drabick | MD | ||
 |
Monika | Joshi | MD, MRCP | ||
 |
Matthew G. | Kaag | MD | ||
 |
Jay | Raman | MD | ||
 |
Nabeel | Sarwani | MD | ||
 |
Leonard | Tuanquin | MD |
Research into genitourinary and prostate cancer at Penn State Cancer Institute is conducted by the genitourinary cancer team. See current clinical trials and members of that team here.
The COVID-19 and Cancer Consortium (CCC19) Registry
Phase III Study of PET-Directed Local or Systemic Therapy Intensification in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)
Prospective evaluation of potential effects of repeated gadoliniumbased contrast agent (GBCA) administrations of the same GBCA on motor and cognitive functions in neurologically normal adults in comparison to a non-GBCA exposed control group ODYSSEY
Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer
Radiopaque Hydrogel Rectal Spacer for Prostate Cancer Radiation Image Guidance
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
NRG-GU011: A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)
A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE) EA8212
A Phase II/III trial of Durvalumab and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy EA8192
Phase III Randomized Trial of Stereotactic ablative radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma (SOAR)
A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)
Phase 1, open label clinical trial to treat Stage IV cancer patients with multiple patient-specific mutated cell surface proteins with chimeric antibodies
NRG-GU013: The Phase III 'High Five Trial' Five Fraction Radiation for High-Risk Prostate Cancer
Creation of a Clinical and Pathologic Tissue Microarray Registry for Radical Cystectomy Specimens
| First Name | Last Name | Title | Role | ||
|---|---|---|---|---|---|
|
Joseph | Drabick | MD | ||
|
Monika | Joshi | MD, MRCP | ||
|
Matthew G. | Kaag | MD | ||
|
Jay | Raman | MD | ||
|
Nabeel | Sarwani | MD | ||
|
Leonard | Tuanquin | MD |